申请人:Sanofi
公开号:US05026711A1
公开(公告)日:1991-06-25
Compounds represented by the general formula: ##STR1## in which R.sub.1 and R.sub.2 are selected from hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.2 -C.sub.6 alkenyl , phenyl or benzyl or R.sub.1 and R.sub.2 form together with the nitrogen atom to which they are attached a C.sub.4 -C.sub.8 saturated heterocycle, R.sub.3 is selected from hydrogen, C.sub.1 -C.sub.6 alkyl, phenyl or C.sub.7 -C.sub.9 phenyl-alkyl, R.sub.4 is selected from hydrogen or C.sub.1 -C.sub.4 alkyl, R.sub.5 and R.sub.6 are selected from hydrogen or halogen, C.sub.1 -C.sub.3 or alkoxy, nitro or trifluoromethyl; Z is selected from OH, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.4 alkyl, benzyl, C.sub.4 -C.sub.6 aryl with or without a heteroatom, or NR.sub.8 R.sub.9, R.sub.8 and R.sub.9 being selected from hydrogen, C.sub.1 -C.sub.4 alkyl, phenyl or benzyl; R.sub.10 is selected from hydrogen, C.sub.1 -C.sub.4 alkyl or phenyl; n is 0, 1 or 3, p is 0 or 1 and one of the symbols A, B, C, D represents N and the others CH or A, B, C, D all represent CH and their acid addition salts, and their salts with bases. The compounds are useful in the prevention and treatment of cardiovascular diseases, as anti-allergic drugs, in the prevention and treatment of infectious states, and for the treatment of anxiety.
该通用公式代表的化合物为:##STR1## 其中R.sub.1和R.sub.2从氢,C.sub.1 -C.sub.6烷基或C.sub.2 -C.sub.6烯基,苯基或苄基中选择,或者R.sub.1和R.sub.2与它们所附着的氮原子一起形成一个C.sub.4 -C.sub.8饱和杂环;R.sub.3从氢,C.sub.1 -C.sub.6烷基,苯基或C.sub.7 -C.sub.9苯基-烷基中选择;R.sub.4从氢或C.sub.1 -C.sub.4烷基中选择;R.sub.5和R.sub.6从氢或卤素,C.sub.1 -C.sub.3或烷氧基,硝基或三氟甲基中选择;Z从OH,C.sub.1 -C.sub.6烷氧基,C.sub.1 -C.sub.4烷基,苄基,C.sub.4 -C.sub.6含或不含杂原子的芳基,或NR.sub.8R.sub.9中选择,其中R.sub.8和R.sub.9从氢,C.sub.1 -C.sub.4烷基,苯基或苄基中选择;R.sub.10从氢,C.sub.1 -C.sub.4烷基或苯基中选择;n为0,1或3,p为0或1,符号A、B、C、D中的一个代表N,其他则代表CH,它们的酸加成盐和碱盐。这些化合物在心血管疾病的预防和治疗、抗过敏药物、预防和治疗感染状态以及焦虑症的治疗中有用。